These results suggest that peripheral toxicities, such as VIPN, may be an important contributor of VCR-induced brain toxicities, indicating that targeting SARM1-mediated peripheral neuropathy may also help mitigate neurocognitive deficits in patients treated with VCR. This evidence concerns the gene SARM1 and peripheral neuropathy.